Sugi Predict

Sugi Predict / Targets / CAPN1

CAPN1

Calpain-1 catalytic subunit · P07384 · CAPN1 on Sugi Atlas →

48,098 patent compounds predicted against CAPN1, 27,829 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL289050 SCHEMBL289050 1.00 20/20
SCHEMBL540737 SCHEMBL540737 1.00 20/20
SCHEMBL540853 SCHEMBL540853 1.00 20/20
SCHEMBL540922 SCHEMBL540922 1.00 20/20
SCHEMBL540966 SCHEMBL540966 1.00 20/20
SCHEMBL541067 SCHEMBL541067 1.00 20/20
SCHEMBL541115 SCHEMBL541115 1.00 20/20
SCHEMBL541155 SCHEMBL541155 1.00 20/20
SCHEMBL541158 SCHEMBL541158 1.00 20/20
SCHEMBL541165 SCHEMBL541165 1.00 20/20
SCHEMBL541212 SCHEMBL541212 1.00 20/20
SCHEMBL541219 SCHEMBL541219 1.00 20/20
SCHEMBL541250 SCHEMBL541250 1.00 20/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL541060) 0.98 20/20
SCHEMBL541065 SCHEMBL541065 0.95 20/20
SCHEMBL540980 SCHEMBL540980 0.93 20/20
SCHEMBL541245 SCHEMBL541245 0.90 20/20
SCHEMBL541037 SCHEMBL541037 0.90 20/20
SCHEMBL541238 SCHEMBL541238 0.90 20/20
SCHEMBL541289 SCHEMBL541289 0.90 20/20

Clinical trials — most relevant to CAPN1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit PHASE2/PHASE3WITHDRAWN
Minocycline for the Treatment of Early-Phase Schizophrenia PHASE3COMPLETED
A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy. PHASE1/PHASE2RECRUITING
Biologic Correlative Taxotere/AC PHASE2COMPLETED
Influence of Morphine or Ketamine or Saline Applied During In-hospital Cardiopulmonary Resuscitation on Early Survival PHASE1UNKNOWN
Evaluation of the Safety and Efficacy of BBM-D101 to Treat Patients with Duchenne Muscular Dystrophy EARLY_PHASE1RECRUITING
Clinical and Biochemical Features for the Identification of Dominant Calpainopathies nanUNKNOWN
LGMD R1 Natural History Study nanACTIVE_NOT_RECRUITING
High Dose Omega-3 Fatty Acids in the Treatment of Sport Related Concussions nanCOMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men nanRECRUITING
Effect of Exercise Training on Protein Expression in Skeletal Muscle Tissue After Exercise in Peripheral Arterial Disease nanCOMPLETED
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract nanUNKNOWN
Congenital Muscle Disease Study of Patient and Family Reported Medical Information nanRECRUITING
Evolution of the Functional and Muscular State of Patients With Muscular Dystrophy 2A Belts nanACTIVE_NOT_RECRUITING
Wolfram Syndrome and WFS1-related Disorders International Registry and Clinical Study nanRECRUITING
Muscle Tissue Bank for Muscular Dystrophy nanCOMPLETED
A Multicenter Phenotype-Genotype Analysis of LGMD Patients in China nanENROLLING_BY_INVITATION
Circulating Markers for Ischemic Heart Disease nanRECRUITING
Apoptosis Markers in Aggressive Periodontitis nanCOMPLETED
Brain Involvement in Dystrophinopathies Part 2 nanCOMPLETED
Relationship of Gestational Age and Urine Concentration of S100B in Preterm and Term Infants in the First Week of Life nanCOMPLETED
SNAP: Measurement of the Subjective Perception of the Symptom in Hereditary Spastic Paraparesis (HSP) nanCOMPLETED
Urine Concentration of S100B in Extremely Premature Infants nanCOMPLETED
A Patient-tailored Genetic/Biomarker/iPSC Combined Approach in ALS - PERMEALS nanRECRUITING
Pediatric Cardiomyopathy Mutation Analysis nanRECRUITING
Association Between Matrix Metalloproteinase-2 Gene Polymorphism rs243865 and Susceptibility to Cataract Development nanCOMPLETED
The Energetic Origin of Neurodegeneration in MS nanCOMPLETED
Genetics of Familial and Sporadic ALS nanCOMPLETED
Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults nanCOMPLETED
Amyotrophic Lateral Sclerosis (ALS) Tissue Donation Program nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CAPN1 binder may also engage these)

ProteinNameSimilarity
Q5NVS7 — 1.000 Q5NVS7 →
Q9GLG2 — 1.000 Q9GLG2 →
Q27970 — 1.000 Q27970 →
P00789 — 1.000 P00789 →
Q92178 — 1.000 Q92178 →
Q27971 — 1.000 Q27971 →
P35750 — 1.000 P35750 →
Q07009 — 1.000 Q07009 →
P97571 — 1.000 P97571 →
O35350 — 1.000 O35350 →
CAPN2 Calpain-2 catalytic subunit 1.000 landscape →
Q9GLG1 — 1.000 Q9GLG1 →
O08529 — 1.000 O08529 →
CAPN9 Calpain-9 0.999 landscape →
Q91VA3 — 0.996 Q91VA3 →
A6NHC0 — 0.996 A6NHC0 →
Q9TTH8 — 0.995 Q9TTH8 →
P20807 — 0.994 P20807 →
Q78EJ9 — 0.994 Q78EJ9 →
P06814 — 0.994 P06814 →
Q64691 — 0.994 Q64691 →
Q9D805 — 0.993 Q9D805 →
Q6J756 — 0.993 Q6J756 →
Q9GLG7 — 0.992 Q9GLG7 →
Q11002 — 0.992 Q11002 →
O35920 — 0.992 O35920 →
P16259 — 0.991 P16259 →
P43368 — 0.991 P43368 →
P27730 — 0.991 P27730 →
Q92177 — 0.990 Q92177 →